Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (Preparatory Stage), Shanghai, People's Republic of China.
General Practice/International Medical Care Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Int J Chron Obstruct Pulmon Dis. 2023 Mar 17;18:349-364. doi: 10.2147/COPD.S391908. eCollection 2023.
To evaluate the real-world situation for the management of chronic obstructive pulmonary disease (COPD) and poorly controlled disease risk factors in the Chinese community.
This retrospective multicentre study analysed data from COPDMICand MICHC in Shanghai Songjiang District, Shanghai, China. The differences in COPD Assessment Test (CAT), the modified Medical Research Council (mMRC) dyspnea scale, and the number of emergency cases, emergency visits, inpatient cases, and hospitalisations from January 2018 to December 2020 were analysed. The impact of coronavirus disease 2019 (COVID-19) on COPD management was also assessed.
For 2020 versus 2018, analysis of 468 COPD cases from COPDMIC matched with MICHC data showed significantly more patients with improved mMRC grades, significantly fewer emergency cases and emergency visits, and significantly fewer hospitalisation cases and hospitalisations. Differences in the number of emergency visits and hospitalisations per capita were statistically significant. Compared to GOLD 3-4, GOLD 1-2 patients showed significant improvements in CAT score, mMRC grade, the number of emergency visits and hospitalisations per capita. Treatment adherence from 2018 to 2020 was 25%, 29.1%, and 6.8%, and the proportion of medication regimens consistent with guidelines was 43.44%, 50.98%, and 71.87%, respectively. Higher treatment adherence resulted in significantly improved CAT scores and mMRC grades and fewer emergency department visits and hospitalisations per capita.
Combined with remote management tools, patients with COPD achieved continuous improvement in symptoms and exacerbations over 3 years. In the context of COVID-19 prevention/control measures, improvements were significant for patients with GOLD 1-2 COPD but limited with GOLD 3-4. Pharmacologic treatment significantly improved clinical symptoms and reduced emergency visits and hospitalisations. Severe airflow limitation and poor adherence to pharmacologic treatment were important risk factors for lack of disease remission.
评估中国社区慢性阻塞性肺疾病(COPD)管理的真实情况和控制不佳的疾病风险因素。
本回顾性多中心研究分析了来自中国上海松江区 COPDMIC 和 MICHC 的数据。比较了 2018 年 1 月至 2020 年 12 月间 COPD 评估测试(CAT)、改良的医学研究委员会(mMRC)呼吸困难量表、急诊病例数、急诊就诊次数、住院病例数和住院次数的差异。同时评估了 2019 年冠状病毒病(COVID-19)对 COPD 管理的影响。
对 468 例 COPDMIC 与 MICHC 数据匹配的 COPD 病例进行分析,结果显示 2020 年较 2018 年 mMRC 分级改善的患者明显增多,急诊病例和急诊就诊次数明显减少,住院病例和住院次数明显减少。人均急诊就诊次数和住院次数的差异具有统计学意义。与 GOLD 3-4 相比,GOLD 1-2 患者的 CAT 评分、mMRC 分级、急诊就诊次数和人均住院次数均显著改善。2018 年至 2020 年的治疗依从性分别为 25%、29.1%和 6.8%,符合指南的药物治疗方案比例分别为 43.44%、50.98%和 71.87%。较高的治疗依从性显著改善了 CAT 评分和 mMRC 分级,减少了人均急诊就诊次数和住院次数。
结合远程管理工具,COPD 患者在 3 年内实现了症状和恶化的持续改善。在 COVID-19 预防/控制措施的背景下,GOLD 1-2 COPD 患者的改善显著,而 GOLD 3-4 COPD 患者的改善有限。药物治疗显著改善了临床症状,减少了急诊就诊次数和住院次数。严重的气流受限和药物治疗依从性差是疾病缓解不足的重要危险因素。